Navigation Links
Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
Date:6/1/2009

the 24-week treatment period, as compared to ibuprofen, in patients at risk for NSAID-induced ulcers. The trials were conducted via a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA).

About HZT-501

HZT-501 is a novel, proprietary fixed-dose tablet combining the world's most prescribed NSAID, ibuprofen, with a high dose of the most potent H2 antagonist, famotidine, in a single pill. It is anticipated that HZT-501 will provide effective pain relief and reduce stomach acidity during the peak time of ulceration risk, thus reducing the risk of NSAID-induced ulcers.

About the Arthritis and Pain Market

According to the Arthritis Foundation, arthritis affects 46 million people in the U.S. and costs the U.S. economy $128 billion annually. According to a study by the Centers for Disease Control and Prevention (CDC) for the National Arthritis Data Workgroup, due to the increasing aging population, arthritis is projected to increase by 40 percent in the next two decades. The CDC estimates that 67 million people will be affected by arthritis by 2030. Additionally, chronic pain affects an estimated 86 million American adults. NSAIDs are among the most widely used drugs in the world for the treatment of arthritis and pain and are a major cause of GI complications, including ulcers. NSAIDs block enzymes and reduce prostaglandins throughout the body and as a consequence, ongoing inflammation, pain, and fever are reduced. Because the prostaglandins that protect the stomach are reduced, NSAIDs often cause ulcers in the stomach. NSAID-induced GI toxicity causes an estimated 16,500 deaths and more than 107,000 hospitalizations annually in the U.S. alone.

If deaths from the gastrointestinal effects of NSAIDs were tabulated separately in the National Vital Statistics reports, these effects would equate to the 15th most common cause of death in the U.S. Studies h
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
2. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
3. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
4. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
5. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
6. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research ... and Drug Administration (FDA) has given the company permission ... AS2-1 in patients > 3 months of age with ... be placed in one of five treatment groups based ... received prior treatment for DIPG. The primary study endpoint ...
(Date:10/25/2014)... N.C. , Oct. 24, 2014  As ... can provide a company access to diverse skill ... markets, and round-the clock business hours for efficiency. ... difficult hurdles. According to recent ... disappointments, such as seeing a project not move ...
(Date:10/22/2014)...  Cephasonics, a technology-innovation leader with a game-changing embedded-ultrasound ... Ultrasound Box™-1), the first product in a new family ... Cephasonics for purchase by companies to rebrand with their ... showcasing the cQUB-1 for the first time at CMEF ... Chongqing, China from October 23 to 26. ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3
... April 27, 2011 ACCESS PHARMACEUTICALS, ... leveraging its proprietary drug-delivery platforms to develop treatments in areas ... Nursing Society (ONS) Congress at the Boston Convention and Exhibition ... (#652) will be displayed in the Exhibition Hall of the ...
... PharmaTech (Cayman) Inc. (NYSE: WX ) today ... 20-F for the year ended December 31, 2010 with ... be accessed on WuXi PharmaTech,s website at http://www.wuxiapptec.com ... provide a hard copy of its annual report on ...
Cached Medicine Technology:Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 2Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 3
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets for ... prices. Bob Seger & The Silver Bullet Band tickets ... are going on sale October 25 and are expected ... browse the selection of tickets for Bob Seger & ... singer is touring North America beginning next month, and ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival in a ... his combination drug therapy became too toxic. Click ... on the Surviving Mesothelioma website. , A new ... suggests that “maintenance therapy” with pemetrexed may be the ... higher doses of cisplatin. , “Although the standard ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, ... sores -- herpes simplex -- might increase the risk of ... fact, being a carrier of certain antibodies to the virus ... "The identification of a treatable cause [herpes simplex] ... lead researcher Dr. Hugo Lovheim, an associate professor in the ...
(Date:10/25/2014)... (HealthDay News) -- A large influx of international aid ... avoid tens of thousands of deaths from the widening ... Using a specially designed mathematical model, the ... in just one densely populated county of hard-hit Liberia ... Monrovia. The researchers said that if international aid ...
(Date:10/25/2014)... shorter, darker days can trigger a type of depression, ... People affected by seasonal affective disorder, also ... even have trouble getting out of bed. In extreme ... Halaris, a professor in the department of psychiatry and ... Medicine. "Seasonal affective disorder should not be taken ...
Breaking Medicine News(10 mins):Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... Steve Pasierb, President , , ... (MTF) indicates the continuation of a promising trend of declining usage ... crack -- among our country,s teens. However, it also indicates several ... Progress , The long-term ...
... and Uplifting TV Movie Portrayal of Tourette Syndrome , ... Nearly 12 million people watched last Sunday night,s Hallmark Hall ... movie based on the true story of a young man,s ... an award winning teacher. The national Tourette Syndrome Association, ...
... - Scientists in the clinic and the laboratory continue ... with breakthrough drugs. With tamoxifen,s discovery 30 years behind ... researchers are studying zoledronic acid, aromatase inhibitors and monoclonal ... presented at the CTRC-AACR San Antonio Breast Cancer Symposium. ...
... Sister Carol Keehan, DC, president and chief executive officer ... issued the following statement: , , ... nomination today of former Senate Majority Leader Tom Daschle to ... person to oversee a new White House Office of Health ...
... The following is a statement by Matthew L. Myers, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) , ... health that the 2008 Monitoring the Future survey released today ... have declined to the lowest levels recorded in this survey ...
... DNA, study says , , THURSDAY, Dec. 11 (HealthDay ... of DNA damage from prolonged exposure to cosmic ionizing ... pilots to 50 university faculty members from the same ... analyzed for DNA abnormalities, specifically the number of times ...
Cached Medicine News:Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 3Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:Cancer drugs in the pipeline 2Health News:Catholic Health Association Statement on the Naming of Tom Daschle and Jeanne Lambrew to Health Leadership Positions in President-Elect Obama's Administration 2Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 2Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 3Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 4Health News:Pilots May Face Greater Cancer Risk 2
... high-quality light guide cables work in conjunction ... optimal brightness during a number of procedures. ... you the flexibility and ease-of-use necessary to ... fully-autoclavable so they can be easily cleaned ...
... line of affordable, high-quality light guide cables ... sources to provide optimal brightness during a ... durable design give you the flexibility and ... And each is fully-autoclavable so they can ...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
Medicine Products: